
The Covid-19 vaccine developed by Novavax has been approved for children aged 12 to 17 years old in Britain.
The Nuvaxovid was approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

The Covid-19 vaccine developed by Novavax has been approved for children aged 12 to 17 years old in Britain.
The Nuvaxovid was approved by the Medicines and Healthcare products Regulatory Agency (MHRA).